Dorsey & Whitney Trust CO LLC Increases Position in Zoetis Inc. $ZTS

Key Points

• Dorsey & Whitney Trust CO LLC increased its stake in Zoetis Inc. by 47.1%, owning 5,778 shares worth approximately $951,000 as of the latest SEC filing.
• Several institutional investors have significantly boosted their holdings in Zoetis, indicating a strong interest in the company's stock, which is now 92.80% owned by institutional investors.
• Zoetis reported an earnings per share of $1.76 for the latest quarter, beating estimates, with a revenue increase of 4.2% year-over-year, leading to a positive outlook for future earnings growth.

Dorsey & Whitney Trust CO LLC increased its holdings in shares of Zoetis Inc. (NYSE:ZTS - Free Report) by 47.1% in the 1st quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 5,778 shares of the company's stock after purchasing an additional 1,851 shares during the period. Dorsey & Whitney Trust CO LLC's holdings in Zoetis were worth $951,000 at the end of the most recent quarter.

A number of other hedge funds have also added to or reduced their stakes in the stock. GM Advisory Group LLC raised its holdings in Zoetis by 6.9% during the 1st quarter. GM Advisory Group LLC now owns 2,298 shares of the company's stock valued at $378,000 after acquiring an additional 149 shares during the period. T. Rowe Price Investment Management Inc. boosted its position in Zoetis by 1,250.6% during the first quarter. T. Rowe Price Investment Management Inc. now owns 48,986 shares of the company's stock valued at $8,066,000 after buying an additional 45,359 shares during the period. Breed s Hill Capital LLC grew its stake in shares of Zoetis by 2.1% in the first quarter. Breed s Hill Capital LLC now owns 3,683 shares of the company's stock worth $606,000 after purchasing an additional 77 shares during the last quarter. Capital Analysts LLC lifted its holdings in Zoetis by 7.9% in the first quarter. Capital Analysts LLC now owns 62,275 shares of the company's stock worth $10,254,000 after buying an additional 4,562 shares during the period. Finally, Banco Bilbao Vizcaya Argentaria S.A. raised its holdings in Zoetis by 44.2% in the 1st quarter. Banco Bilbao Vizcaya Argentaria S.A. now owns 20,500 shares of the company's stock worth $3,358,000 after acquiring an additional 6,281 shares during the last quarter. Institutional investors and hedge funds own 92.80% of the company's stock.

Insider Buying and Selling at Zoetis

In related news, EVP Roxanne Lagano sold 652 shares of the company's stock in a transaction dated Tuesday, June 3rd. The shares were sold at an average price of $170.00, for a total transaction of $110,840.00. Following the completion of the transaction, the executive vice president owned 15,129 shares in the company, valued at $2,571,930. This represents a 4.13% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. 0.16% of the stock is currently owned by company insiders.

Zoetis Stock Performance

Shares of NYSE:ZTS traded up $0.7080 on Friday, hitting $156.3180. 2,426,297 shares of the company were exchanged, compared to its average volume of 3,450,163. The firm has a market capitalization of $69.28 billion, a P/E ratio of 26.91, a price-to-earnings-growth ratio of 2.51 and a beta of 0.88. The stock's 50 day moving average price is $153.84 and its 200 day moving average price is $158.52. Zoetis Inc. has a 1-year low of $139.70 and a 1-year high of $200.33. The company has a current ratio of 1.76, a quick ratio of 1.04 and a debt-to-equity ratio of 1.05.

Zoetis (NYSE:ZTS - Get Free Report) last posted its earnings results on Tuesday, August 5th. The company reported $1.76 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $1.62 by $0.14. Zoetis had a net margin of 27.83% and a return on equity of 56.90%. The company had revenue of $2.46 billion during the quarter, compared to the consensus estimate of $2.41 billion. During the same period in the previous year, the firm posted $1.56 earnings per share. The firm's quarterly revenue was up 4.2% on a year-over-year basis. Zoetis has set its FY 2025 guidance at 6.300-6.400 EPS. Sell-side analysts predict that Zoetis Inc. will post 6.07 EPS for the current year.

Analysts Set New Price Targets

A number of brokerages have recently issued reports on ZTS. UBS Group cut their price objective on shares of Zoetis from $189.00 to $170.00 and set a "neutral" rating for the company in a research report on Wednesday, May 7th. Stifel Nicolaus downgraded shares of Zoetis from a "buy" rating to a "hold" rating and lowered their price target for the company from $165.00 to $160.00 in a report on Wednesday, June 18th. Leerink Partnrs downgraded shares of Zoetis from a "strong-buy" rating to a "hold" rating in a research note on Thursday, July 17th. Piper Sandler raised their target price on shares of Zoetis from $210.00 to $215.00 and gave the stock an "overweight" rating in a research report on Monday, August 11th. Finally, Leerink Partners lowered shares of Zoetis from an "outperform" rating to a "market perform" rating and cut their price objective for the company from $180.00 to $155.00 in a report on Thursday, July 17th. Four research analysts have rated the stock with a Buy rating and four have assigned a Hold rating to the stock. Based on data from MarketBeat, the company currently has an average rating of "Moderate Buy" and an average price target of $202.43.

Zoetis Company Profile

Zoetis Inc engages in the discovery, development, manufacture, and commercialization of animal health medicines, vaccines, and diagnostic products and services in the United States and internationally. The company commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep and others; and companion animals comprising dogs, cats, and horses.